Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ:BIOA)

5.180 +0.070 (+1.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioAge Labs, Inc. - Common Stock

BioAge Labs (BIOA) Q2 Revenue Hits $2.4M
Via The Motley Fool
Topics Intellectual Property
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Crude Oil Gains 2%; BioAge Labs Shares Plunge
 
Via Benzinga
Nasdaq Down Over 100 Points; US Wholesale Inventories Rise By 0.2%
 
Via Benzinga
Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
BioAge Labs halts STRIDES Phase 2 trial of azelaprag after liver enzyme elevations, plans further analysis with updates expected in Q1 2025. 
Via Benzinga
Topics Initial Public Offering
Why Interpublic Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Self-Driving Startup Pony.ai Files For U.S. IPO
Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group... 
Via Talk Markets
Topics Initial Public Offering
Prediction: These 2 Stocks Could Soar in 2025
The key word here is "could." 
Via The Motley Fool
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
The future of the weight loss market might not revolve around GLP-1 drugs. 
Via The Motley Fool
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm. 
Via The Motley Fool
Topics Initial Public Offering
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
One of these businesses is a risky play, but the other is very likely to succeed. 
Via The Motley Fool
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October
There's a chance that its lead candidate could become one of the top drugs ever. 
Via The Motley Fool
This IPO Biotech Stock Could Be the Next Eli Lilly
BioAge has its eyes on a handful of truly gargantuan markets. 
Via The Motley Fool
Topics Initial Public Offering
Obesity Drug Developer BioAge Makes Nasdaq Debut
Shares of BioAge Labs opened for trading this week, with the company planning to use the proceeds of its initial public offering to take its lead obesity drug further into clinical trials. 
Via Talk Markets
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
The company is working on a drug that mimics apelin, which is released following exercise. 
Via Investor's Business Daily
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.